Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin, thereby preventing fibrin formation and thrombus propagation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
For treatment of venous thromboembolism: Initial IV bolus of 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For prophylaxis: Subcutaneous injection of 5000 units every 8-12 hours. Heparin sodium 12,500 units/250 mL (50 units/mL) is typically used for continuous IV infusion.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is dose-dependent: for bolus doses of 100, 400, and 800 U/kg, half-lives are approximately 1, 2.5, and 5 hours, respectively. In severe renal impairment, half-life may be prolonged.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal (primarily via reticuloendothelial system depolymerization; elimination of metabolites in urine; minimal unchanged drug excreted renally). Approximately 50% of a dose is eliminated renally as metabolites.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte